Aclaris Therapeutics Reports 36% Revenue Decline and $15.4 Million Net Loss in Q2 2025

Aclaris Therapeutics, Inc. reported a total revenue of $1.8 million for the second quarter of 2025, a decrease of 36% compared to $2.8 million in the same period of 2024. For the first half of 2025, the company generated $3.2 million in revenue, down from $5.2 million in the first half of 2024. The decline in revenue was primarily attributed to reduced contract research and licensing revenues, with contract research revenue falling to $442,000 from $625,000 year-over-year, and licensing revenue decreasing from $2.1 million to $1.3 million. The company reported a net loss of $15.4 million for the second quarter, compared to a loss of $11 million in the prior year, and a total net loss of $30.5 million for the first half of 2025, up from $27.9 million in the same period of 2024.

In terms of operational changes, Aclaris has made significant adjustments to its workforce, reducing its headcount by approximately 46% in December 2023, which was completed by the end of 2024. This restructuring was aimed at streamlining operations and reducing costs. The company also initiated a Phase 2 trial for its investigational drug bosakitug in June 2025, which is designed to treat moderate to severe atopic dermatitis. Additionally, Aclaris has been actively pursuing strategic partnerships to further develop its product candidates, including a recent exclusive license agreement with Biosion for the development of bosakitug and ATI-052.

As of June 30, 2025, Aclaris reported cash, cash equivalents, and marketable securities totaling $180.9 million, a slight decrease from $220.3 million at the end of 2024. The company’s accumulated deficit reached $933.4 million, reflecting ongoing investments in research and development. Aclaris has indicated that it will require additional capital to support its operations and product development efforts, particularly as it continues to incur significant expenses related to clinical trials and regulatory activities.

Looking ahead, Aclaris anticipates continued net losses as it advances its product candidates through clinical development. The company is focused on securing additional funding through equity sales, potential partnerships, and other strategic transactions. Aclaris has expressed confidence that its existing cash reserves are sufficient to fund operations for at least the next 12 months, but acknowledges that its ability to raise additional capital may be impacted by broader economic conditions, including inflation and geopolitical tensions. The company remains committed to its long-term strategy of developing innovative therapies for immuno-inflammatory diseases.